Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed prostate cancer with progressive disease~* Evidence of castration resistance defined as disease progression despite a testosterone level \< 50ng/dL (or surgical castration)~* Evidence of metastatic disease to the bones within the lumbar spine, sacrum, or pelvic bones that is identifiable on screening pelvic MRI~* If patient has had prior pelvis radiation therapy (RT), then bone metastases must be out of radiated port (e.g. lumbar or sacral spine)~* Any prior therapy for castrate disease acceptable other than prior XL184 with a minimum washout of 28 days for any other anticancer therapy~* Patients with castrate resistant disease post antiandrogen therapy/withdrawal must meet at least one of the following criteria:~  * Have not received docetaxel chemotherapy~ * Have received docetaxel chemotherapy but received less then 225mg/m2 cumulative dose~ * Have documented liver metastases~ * Have no pain or pain that does not require a long acting (SR) narcotic~ * Have received mitoxantrone chemotherapy in the past for CRPC~Exclusion Criteria:~* Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study~* Patients who are receiving any other investigational agents~* Prior treatment with other vascular endothelial growth factor (VEGF) or c-MET targeted therapies~* History of hematemesis or hemoptysis~* The subject has uncontrolled or significant intercurrent illness~* The patient requires concomitant treatment, in therapeutic doses, with anticoagulants

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (enzyme inhibitor therapy) (Type: EXPERIMENTAL): Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).